332PRibociclib (RIB) + letrozole (LET) in patients (pts)...

Annals of Oncology 2019 / 10 Vol. 30; Iss. Supplement

332PRibociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial

De Laurentiis, M, Ring, A, Campone, M, Bachelot, T, Jacot, W, Marchetti, P, Timcheva, C, De Valk, B, Gombos, A, Menon-Singh, L, Wu, J, Zhou, K, Neven, P
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz242.027
Date:
October, 2019
File:
PDF, 87 KB
2019
Conversion to is in progress
Conversion to is failed